|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T:
Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
West NR, McCuaig S, Franchini F and Powrie
F: Emerging cytokine networks in colorectal cancer. Nat Rev
Immunol. 15:615–629. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hebenstreit D, Wirnsberger G, Horejs-Hoeck
J and Duschl A: Signaling mechanisms, interaction partners, and
target genes of STAT6. Cytokine Growth Factor Rev. 17:173–188.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chua KH, Ng JG, Ng CC, Hilmi I, Goh KL and
Kee BP: Association of NOD1, CXCL16, STAT6 and TLR4 gene
polymorphisms with Malaysian patients with Crohn's disease. Peerj.
4:e18432016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Klein W, Tromm A, Folwaczny C, Hagedorn M,
Duerig N, Epplen J, Schmiegel W and Griga T: The G2964A
polymorphism of the STAT6 gene in inflammatory bowel disease. Dig
Liver Dis. 37:159–161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xia B, Crusius JB, Wu J, Zwiers A, van
Bodegraven AA and Pena AS: Signal transducer and activator of
transcription 6 gene G2964A polymorphism and inflammatory bowel
disease. Clin Exp Immunol. 131:446–450. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mueller TD, Zhang JL, Sebald W and Duschl
A: Structure, binding, and antagonists in the IL-4/IL-13 receptor
system. Biochim Biophys Acta. 1592:237–250. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Murata T, Noguchi PD and Puri RK:
Receptors for interleukin (IL)-4 do not associate with the common
gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine
kinase in human colon carcinoma cells. J Biol Chem.
270:30829–30836. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sengupta S, Thaci B, Crawford AC and
Sampath P: Interleukin-13 receptor alpha 2-targeted glioblastoma
immunotherapy. Biomed Res Int. 2014:9521282014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mikita T, Campbell D, Wu P, Williamson K
and Schindler U: Requirements for interleukin-4-induced gene
expression and functional characterization of Stat6. Mol Cell Biol.
16:5811–5820. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gupta S, Jiang M and Pernis AB: IFN-alpha
activates Stat6 and leads to the formation of Stat2:Stat6 complexes
in B cells. J Immunol. 163:3834–3841. 1999.PubMed/NCBI
|
|
14
|
Dickensheets H, Vazquez N, Sheikh F,
Gingras S, Murray PJ, Ryan JJ and Donnelly RP: Suppressor of
cytokine signaling-1 is an IL-4-inducible gene in macrophages and
feedback inhibits IL-4 signaling. Genes Immun. 8:21–27. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Deuring J, Peppelenbosch MP, Kuipers
EJ, de Haar C and van der Woude CJ: STAT1, STAT6 and adenosine
3′,5′-cyclic monophosphate (cAMP) signaling drive SOCS3 expression
in inactive ulcerative colitis. Mol Med. 18:1412–1419. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hanson EM, Dickensheets H, Qu CK, Donnelly
RP and Keegan AD: Regulation of the dephosphorylation of Stat6.
Participation of Tyr-713 in the interleukin-4 receptor alpha, the
tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem.
278:3903–3911. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu X, Malumbres R, Shields B, Jiang X,
Sarosiek KA, Natkunam Y, Tiganis T and Lossos IS: PTP1B is a
negative regulator of interleukin 4-induced STAT6 signaling. Blood.
112:4098–4108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen W, Daines MO and Hershey GK:
Methylation of STAT6 modulates STAT6 phosphorylation, nuclear
translocation, and DNA-binding activity. J Immunol. 172:6744–6750.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Di Stefano AB, Iovino F, Lombardo Y,
Eterno V, Höger T, Dieli F, Stassi G and Todaro M: Survivin is
regulated by interleukin-4 in colon cancer stem cells. J Cell
Physiol. 225:555–561. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang F, Wang D, Yao YL and Wang M: PDGF
signaling in cancer progression. Int J Clin Exp Med. 10:9918–9929.
2017.
|
|
21
|
Patel BK, Wang LM, Lee CC, Taylor WG,
Pierce JH and LaRochelle WJ: Stat6 and Jak1 are common elements in
platelet-derived growth factor and interleukin-4 signal
transduction pathways in NIH 3T3 fibroblasts. J Biol Chem.
271:22175–22182. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ingram JL, Antao-Menezes A, Mangum JB,
Lyght O, Lee PJ, Elias JA and Bonner JC: Opposing actions of Stat1
and Stat6 on IL-13-induced up-regulation of early growth response-1
and platelet-derived growth factor ligands in pulmonary
fibroblasts. J Immunol. 177:4141–4148. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jess T, Rungoe C and Peyrin-Biroulet L:
Risk of colorectal cancer in patients with ulcerative colitis: A
meta-analysis of population-based cohort studies. Clin
Gastroenterol Hepatol. 10:639–645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
von Roon AC, Reese G, Teare J,
Constantinides V, Darzi AW and Tekkis PP: The risk of cancer in
patients with Crohn's disease. Dis Colon Rectum. 50:839–855. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rosen MJ, Frey MR, Washington MK,
Chaturvedi R, Kuhnhein LA, Matta P, Revetta FL, Wilson KT and Polk
DB: STAT6 activation in ulcerative colitis: A new target for
prevention of IL-13-induced colon epithelial cell dysfunction.
Inflamm Bowel Dis. 17:2224–2234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H
and Wang S: EZH2 and STAT6 expression profiles are correlated with
colorectal cancer stage and prognosis. World J Gastroenterol.
16:2421–2427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F and Galon J: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Formentini A, Braun P, Fricke H, Link KH,
Henne-Bruns D and Kornmann M: Expression of interleukin-4 and
interleukin-13 and their receptors in colorectal cancer. Int J
Colorectal Dis. 27:1369–1376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rosen MJ, Chaturvedi R, Washington MK,
Kuhnhein LA, Moore PD, Coggeshall SS, McDonough EM, Weitkamp JH,
Singh AB, Coburn LA, et al: STAT6 deficiency ameliorates severity
of oxazolone colitis by decreasing expression of claudin-2 and
Th2-inducing cytokines. J Immunol. 190:1849–1858. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hoving JC, Kirstein F, Nieuwenhuizen NE,
Fick LC, Hobeika E, Reth M and Brombacher F: B Cells that produce
immunoglobulin E mediate Colitis in BALB/c mice. Gastroenterology.
142:96–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Buzza MS, Johnson TA, Conway GD, Martin
EW, Mukhopadhyay S, Shea-Donohue T and Antalis TM: Inflammatory
cytokines down-regulate the barrier-protective prostasin-matriptase
proteolytic cascade early in experimental colitis. J Biol Chem.
292:10801–10812. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shajib MS, Wang HQ, Kim JJ, Sunjic I, Ghia
JE, Denou E, Collins M, Denburg JA and Khan WI: Interleukin 13 and
Serotonin: Linking the immune and endocrine systems in murine
models of intestinal inflammation. PLoS One. 8:e727742013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leon-Cabrera SA, Molina-Guzman E,
Delgado-Ramirez YG, Vázquez-Sandoval A, Ledesma-Soto Y,
Pérez-Plasencia CG, Chirino YI, Delgado-Buenrostro NL,
Rodríguez-Sosa M, Vaca-Paniagua F, et al: Lack of STAT6 attenuates
inflammation and drives protection against early steps of
colitis-associated colon cancer. Cancer Immunol Res. 5:385–396.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jayakumar A and Bothwell ALM: Stat6
promotes intestinal tumorigenesis in a mouse model of adenomatous
polyposis by expansion of MDSCs and inhibition of cytotoxic CD8
response. Neoplasia. 19:595–605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Oliveira T, Ramakrishnan M, Diamanti
MA, Ziegler PK, Brombacher F and Greten FR: Loss of Stat6 affects
chromatin condensation in intestinal epithelial cells causing
diverse outcome in murine models of inflammation-associated and
sporadic colon carcinogenesis. Oncogene. 38:1787–1801. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wick EC, LeBlanc RE, Ortega G, Robinson C,
Platz E, Pardoll DM, Iacobuzio-Donahue C and Sears CL: Shift from
pStat6 to pStat3 predominance is associated with inflammatory bowel
disease-associated dysplasia. Inflamm Bowel Dis. 18:1267–1274.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao H, Zhang J, Liu H, Wan L, Zhang H,
Huang Q, Xu E and Lai M: IL-13/STAT6 signaling plays a critical
role in the epithelial-mesenchymal transition of colorectal cancer
cells. Oncotarget. 7:61183–61198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang L, Cheng Q, Zhang B and Zhang M:
IL-13 induces the expression of 11βHSD2 in IL-13Rα2 dependent
manner and promotes the malignancy of colorectal cancer. Am J
Transl Res. 8:1064–1072. 2016.PubMed/NCBI
|
|
39
|
Barderas R, Bartolome RA,
Fernandez-Acenero MJ, Torres S and Casal JI: High expression of
IL-13 receptor α2 in colorectal cancer is associated with invasion,
liver metastasis, and poor prognosis. Cancer Res. 72:2780–2790.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen J, Gong C, Mao H, Li Z, Fang Z, Chen
Q, Lin M, Jiang X, Hu Y, Wang W, et al: E2F1/SP3/STAT6 axis is
required for IL-4-induced epithelial-mesenchymal transition of
colorectal cancer cells. Int J Oncol. 53:567–578. 2018.PubMed/NCBI
|
|
41
|
Todaro M, Lombardo Y, Francipane MG, Alea
MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A,
Condorelli G, et al: Apoptosis resistance in epithelial tumors is
mediated by tumor-cell-derived interleukin-4. Cell Death Differ.
15:762–772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu H, Antony S, Roy K, Juhasz A, Wu Y, Lu
J, Meitzler JL, Jiang G, Polley E and Doroshow JH: Interleukin-4
and interleukin-13 increase NADPH oxidase 1-related proliferation
of human colon cancer cells. Oncotarget. 8:38113–38135. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kanai T, Watanabe M, Hayashi A, Nakazawa
A, Yajima T, Okazawa A, Yamazaki M, Ishii H and Hibi T: Regulatory
effect of interleukin-4 and interleukin-13 on colon cancer cell
adhesion. Br J Cancer. 82:1717–1723. 2000.PubMed/NCBI
|
|
44
|
Binnemars-Postma K, Bansal R, Storm G and
Prakash J: Targeting the Stat6 pathway in tumor-associated
macrophages reduces tumor growth and metastatic niche formation in
breast cancer. FASEB J. 32:969–978. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Linde N, Lederle W, Depner S, van Rooijen
N, Gutschalk CM and Mueller MM: Vascular endothelial growth
factor-induced skin carcinogenesis depends on recruitment and
alternative activation of macrophages. J Pathol. 227:17–28. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ostrand-Rosenberg S, Sinha P, Clements V,
Dissanayake SI, Miller S, Davis C and Danna E: Signal transducer
and activator of transcription 6 (Stat6) and CD1: Inhibitors of
immunosurveillance against primary tumors and metastatic disease.
Cancer Immunol Immunother. 53:86–91. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Conticello C, Pedini F, Zeuner A, Patti M,
Zerilli M, Stassi G, Messina A, Peschle C and De Maria R: IL-4
protects tumor cells from anti-CD95 and chemotherapeutic agents via
up-regulation of antiapoptotic proteins. J Immunol. 172:5467–5477.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Francipane MG, Alea MP, Lombardo Y, Todaro
M, Medema JP and Stassi G: Crucial role of interleukin-4 in the
survival of colon cancer stem cells. Cancer Res. 68:4022–4025.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li BH, Yang XZ, Li PD, Yuan Q, Liu XH,
Yuan J and Zhang WJ: IL-4/Stat6 activities correlate with apoptosis
and metastasis in colon cancer cells. Biochem Biophys Res Commun.
369:554–560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li BH, Xu SB, Li F, Zou XG, Saimaiti A,
Simayi D, Wang YH, Zhang Y, Yuan J and Zhang WJ: Stat6
activity-related Th2 cytokine profile and tumor growth advantage of
human colorectal cancer cells in vitro and in vivo. Cell Signal.
24:718–725. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Volonte A, Di Tomaso T, Spinelli M, Todaro
M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E,
Ferrone S, et al: Cancer-initiating cells from colorectal cancer
patients escape from T cell-mediated immunosurveillance in vitro
through membrane-bound IL-4. J Immunol. 192:523–532. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cosin-Roger J, Ortiz-Masia D, Calatayud S,
Hernandez C, Esplugues JV and Barrachina MD: The activation of Wnt
signaling by a STAT6-dependent macrophage phenotype promotes
mucosal repair in murine IBD. Mucosal Immunol. 9:986–998. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mendoza-Rodriguez MG, Sanchez-Barrera CA,
Callejas BE, García-Castillo V, Beristain-Terrazas DL,
Delgado-Buenrostro NL, Chirino YI, León-Cabrera SA, Rodríguez-Sosa
M, Gutierrez-Cirlos EB, et al: Use of STAT6 Phosphorylation
inhibitor and trimethylglycine as new adjuvant therapies for
5-fluorouracil in colitis-associated tumorigenesis. Int J Mol Sci.
21(pii): E21302020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nappo G, Handle F, Santer FR, McNeill RV,
Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ and Erb HHH:
The immunosuppressive cytokine interleukin-4 increases the
clonogenic potential of prostate stem-like cells by activation of
STAT6 signalling. Oncogenesis. 6:e3422017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu K, Tao W and Su Z: Propofol prevents
IL-13-induced epithelial-mesenchymal transition in human colorectal
cancer cells. Cell Biol Int. 42:985–993. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Healey GD, Lockridge JA, Zinnen S, Hopkin
JM, Richards I and Walker W: Development of pre-clinical models for
evaluating the therapeutic potential of candidate siRNA targeting
STAT6. PLoS One. 9:e903382014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bartolome RA, Jaen M and Casal JI: An
IL13Rα2 peptide exhibits therapeutic activity against metastatic
colorectal cancer. Br J Cancer. 119:940–949. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gharib AF, Shalaby SM, Raafat N, Fawzy WMS
and Abdel Hakim NH: Assessment of neutralizing interleukin-4 effect
on CD133 gene expression in colon cancer cell line. Cytokine.
97:66–72. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Todaro M, Perez Alea M, Scopelliti A,
Medema JP and Stassi G: IL-4-mediated drug resistance in colon
cancer stem cells. Cell Cycle. 7:309–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Todaro M, Alea MP, Di Stefano AB,
Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G,
Medema JP and Stassi G: Colon cancer stem cells dictate tumor
growth and resist cell death by production of interleukin-4. Cell
Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rivankar S: An overview of doxorubicin
formulations in cancer therapy. J Cancer Res Ther. 10:853–858.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yang CY, Liu HW, Tsai YC, Tseng JY, Liang
SC, Chen CY, Lian WN, Wei MC, Lu M, Lu RH, et al: Interleukin-4
receptor-targeted liposomal doxorubicin as a model for enhancing
cellular uptake and antitumor efficacy in murine colorectal cancer.
Cancer Biol Ther. 16:1641–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y
and Laurence A: Janus kinase inhibitors in autoimmune diseases. Ann
Rheum Dis. 72 (Suppl 2):ii111–ii115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Regenbogen T, Chen L, Trinkaus K,
Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim
KH, et al: Pacritinib to inhibit JAK/STAT signaling in refractory
metastatic colon and rectal cancer. J Gastrointest Oncol.
8:985–989. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pardanani A and Tefferi A: How I treat
myelofibrosis after failure of JAK inhibitors. Blood. 132:492–500.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fogelman D, Cubillo A, Garcia-Alfonso P,
Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM,
Cohn A, et al: Randomized, double-blind, phase two study of
ruxolitinib plus regorafenib in patients with relapsed/refractory
metastatic colorectal cancer. Cancer Med. 7:5382–5393. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shimaoka H, Takeno S, Maki K, Sasaki T,
Hasegawa S and Yamashita Y: A cytokine signal inhibitor for
rheumatoid arthritis enhances cancer metastasis via depletion of NK
cells in an experimental lung metastasis mouse model of colon
cancer. Oncol Lett. 14:3019–3027. 2017. View Article : Google Scholar : PubMed/NCBI
|
